Form 4 for RPRX Royalty Pharma plc
Accepted 2026-02-13 00:00:00 ET · period of report 2026-02-11 · accession 0001507678-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-11 | RPRX | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +157.8K | 1.10M | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2026-02-11 | A | A | 157,828 | $0.00 | 1,098,783 | D | — | — | (F1) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. |